In conversation with... Alexandra Durr

from Listen to The Lancet Neurology · host The Lancet

Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology.

Episode metadata supplied by the publisher feed · Published Feb 22, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

In conversation with... Alexandra Durr

0:00 7:55

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Neurology?

This episode is 7 minutes long.

When was this Listen to The Lancet Neurology episode published?

This episode was published on February 22, 2022.

Can I download this Listen to The Lancet Neurology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!